Acalabrutinib (ACP-196)

DRUG2 trials

Sponsors

Acerta Pharma BV

Conditions

Chronic Lymphocytic LeukemiaWaldenström Macroglobulinemia (WM)

Phase 2

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Active, not recruitingNCT02180724

Acerta Pharma BVWaldenström Macroglobulinemia (WM)

Start: 2014-09-11End: 2026-12-31Updated: 2026-09-14

Phase 3

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Active, not recruitingNCT02970318

Acerta Pharma BVChronic Lymphocytic Leukemia

Start: 2017-02-02End: 2027-10-01Updated: 2026-07-24

Related Papers

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

2026-04-15

Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies.

2024-11-124 citations

Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.

Journal of Clinical Oncology2022-06-015 citations

Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia.

Journal of Clinical Oncology2022-06-012 citations

P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP

HemaSphere2022-06-011 citations

PB1887: NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

HemaSphere2022-06-011 citations

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood2021-11-0522 citations

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Haematologica2021-09-3052 citations

Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia

Journal of Patient-Reported Outcomes2021-03-1134 citations

Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood2020-11-048 citations

Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.

Journal of Clinical Oncology2020-05-207 citations

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

2019-12-19109 citations

Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) in Patients with Chronic Lymphocytic Leukemia (CLL)

Blood2019-11-135 citations

Significant Progress Made in CLL, But ‘Home Run’ Therapy Remains Elusive

Oncology Times2019-07-11

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Hematological Oncology2019-06-0126 citations

Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).

Journal of Clinical Oncology2018-05-2011 citations